With the Cancer Immunotherapy market forecast to increase to $9 billion by 2022, it’s no surprise that the burgeoning sector has attracted the attention of biotech and pharma investors across
bluebird bio
About Us
Evolution Bioscience is a global consultancy firm, specialising in market intelligence, strategy formulation, technology transfer and commercialisation services, covering the full range of Biotechnology sectors.Recent Posts
2016 © Evolution Bioscience / Darwin Hutton Partners